



**HAL**  
open science

## **Pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence**

Eva C. Boritsch, Wafa Frigui, Alessandro Cascioferro, Wladimir Malaga,  
Gilles Etienne, Françoise Laval, Alexandre Pawlik, Fabien Le Chevalier,  
Mickael Orgeur, Laurence Ma, et al.

► **To cite this version:**

Eva C. Boritsch, Wafa Frigui, Alessandro Cascioferro, Wladimir Malaga, Gilles Etienne, et al.. Pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence. *Nature Microbiology*, 2016, 1 (février 2016), 10.1038/nmicrobiol.2015.19 . pasteur-01265519

**HAL Id: pasteur-01265519**

**<https://pasteur.hal.science/pasteur-01265519>**

Submitted on 1 Feb 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0  
International License

1 ***pks5*-recombination-mediated surface remodelling in *Mycobacterium tuberculosis***  
2 **emergence**

3

4 Eva C. Boritsch<sup>1</sup>, Wafa Frigui<sup>1</sup>, Alessandro Cascioferro<sup>1</sup>, Wladimir Malaga<sup>2,3</sup>, Gilles  
5 Etienne<sup>2,3</sup>, Françoise Laval<sup>2,3</sup>, Alexandre Pawlik<sup>1</sup>, Fabien Le Chevalier<sup>1,5</sup>, Mickael Orgeur<sup>1</sup>,  
6 Laurence Ma<sup>4</sup>, Christiane Bouchier<sup>4</sup>, Timothy P. Stinear<sup>6</sup>, Philip Supply<sup>7</sup>, Laleh Majlessi<sup>1</sup>,  
7 Mamadou Daffé<sup>2,3</sup>, Christophe Guilhot<sup>2,3,\*</sup> and Roland Brosch<sup>1,\*</sup>.

8

9 <sup>1</sup>Institut Pasteur, Unit for Integrated Mycobacterial Pathogenomics, 75015 Paris, France;

10 <sup>2</sup>CNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale), 31000 Toulouse, France;

11 <sup>3</sup>Université de Toulouse, UPS, IPBS, 31000 Toulouse, France;

12 <sup>4</sup>Institut Pasteur, PF1-Plate-Forme Génomique, Paris, France;

13 <sup>5</sup>University Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, Paris, France

14 <sup>6</sup>Department of Microbiology and Immunology, University of Melbourne, Parkville,  
15 Victoria, Australia.

16 <sup>7</sup>Inserm U1019, CNRS UMR8204, Université de Lille, Institut Pasteur de Lille, Center for  
17 Infection and Immunity, 59000 Lille, France.

18

19 \*Corresponding authors: [Christophe.Guilhot@ipbs.fr](mailto:Christophe.Guilhot@ipbs.fr) and [roland.brosch@pasteur.fr](mailto:roland.brosch@pasteur.fr)

20

21 *Mycobacterium tuberculosis* is a major, globally spread, aerosol-transmitted human pathogen,  
22 thought to have evolved by clonal expansion from a *Mycobacterium canettii*-like progenitor.  
23 In contrast, extant *M. canettii* strains are rare, genetically diverse and geographically  
24 restricted mycobacteria of only marginal epidemiological importance. Here we show that the  
25 contrasting evolutionary success of these two groups is linked to loss of lipooligosaccharide  
26 (LOS) biosynthesis and subsequent morphotype changes. Spontaneous smooth-to-rough *M.*  
27 *canettii* variants were found mutated in the polyketide-synthase-encoding *pks5* locus and  
28 deficient in LOS synthesis; a phenotype restored by complementation. Importantly, these  
29 rough variants showed altered host-pathogen interaction and increased virulence in cellular-  
30 and animal-infection models. In one variant, LOS deficiency occurred via homologous  
31 recombination between two *pks5* copies and removal of the intervening acyltransferase-  
32 encoding gene. The resulting single *pks5* configuration is similar to that fixed in *M.*  
33 *tuberculosis*, known to lack LOS. Our results suggest that *pks5*-recombination-mediated  
34 bacterial surface remodelling increased virulence, driving evolution from putative generalist  
35 mycobacteria towards professional pathogens of mammalian hosts.

36 Tuberculosis is a major human infectious disease. Although many aspects of the disease-  
37 causing potential of its etiological agent *Mycobacterium tuberculosis* are known<sup>1</sup>, our  
38 understanding is scant of the molecular events that favoured its evolutionary success as one of  
39 the most widely distributed human pathogens. New insights into this question are important  
40 for uncovering mechanisms of pathogenesis and new drug targets<sup>2</sup>. Strains of the closely  
41 related and phylogenetically early branching *Mycobacterium canettii*, also named smooth  
42 tubercle bacilli (STB)<sup>3</sup> are powerful resources to investigate the evolution of *M. tuberculosis*  
43 and the *M. tuberculosis* complex (MTBC)<sup>3</sup>. The first strain of *M. canettii* was isolated by  
44 Georges Canetti in 1969 and since then less than 100 isolates have been described, most of  
45 which have been isolated from tuberculosis patients with a connection to the Horn of Africa<sup>4</sup>  
46 <sup>7</sup>. Despite their geographic restriction, *M. canettii* strains show much greater genetic  
47 variability and are less virulent/persistent than *M. tuberculosis*. Genome comparisons suggest  
48 that *M. tuberculosis* evolved by clonal expansion from a pool of *M. canettii*-like tubercle  
49 bacilli through the gain of virulence and persistence mechanisms<sup>3,8,9</sup>. While some genomic  
50 differences were found to be specific for a single *M. canettii* strain, apparently due to isolated  
51 horizontal gene transfer (e.g. the *mce5* operon<sup>3</sup> or the *eptABCD* operon<sup>10</sup>, present exclusively  
52 in strain STB-J)<sup>3</sup>, others are conserved throughout all *M. canettii* strains as a result of  
53 phylogenetic ancestry (e.g. *cobF*, present in *M. canettii* and deleted from the MTBC)<sup>3</sup>.

54 Here we investigated phenotypic differences between *M. canettii* and *M. tuberculosis*  
55 and focused on the unique, conserved, smooth (S) colony morphotype of *M. canettii*, as  
56 opposed to the rough (R) morphotype of MTBC members. Previously, S-morphotypes of non-  
57 tuberculous mycobacterial species such as *Mycobacterium avium*<sup>11</sup>, *Mycobacterium*  
58 *abscessus*<sup>12</sup>, *Mycobacterium kansasii*<sup>13</sup> or *Mycobacterium marinum*<sup>14</sup> have been found to be  
59 less virulent than R-morphotypes, raising the question of whether the highly conserved *M.*  
60 *tuberculosis* R-morphotype might have been the result of evolutionary selection, based on  
61 host-pathogen interactions favouring a more virulent or persistent phenotype. In other  
62 mycobacterial species, S/R variation is often attributed to different kinds of cell surface  
63 glycolipids, such as glycopeptidolipids (GPL) for *M. avium*<sup>15</sup> and *M. abscessus*<sup>16,17</sup> or  
64 lipooligosaccharides (LOS) for *M. kansasii*<sup>13</sup> and *M. marinum*<sup>14,18,19</sup>. Insights from earlier  
65 studies for *M. canettii* have remained abstruse as no specific lipid exclusively present in the S-  
66 morphotype has been identified<sup>20</sup>, nor has the genetic basis for morphotype variation been  
67 determined<sup>4</sup>.

68 Building on recent data from several *M. canettii* genomes<sup>3</sup>, here we studied smooth  
69 and spontaneously converted R-variants of two different *M. canettii* strains, STB-K (CIPT

70 140070010) and STB-I (CIPT 140070007)<sup>3</sup>, hereafter named K<sub>S/R</sub> and I<sub>S/R</sub>, respectively. We  
71 used whole genome sequencing (WGS) and identified differences in genes of the *pks5* locus,  
72 which in *Mycobacterium smegmatis*, *M. marinum* or *M. kansasii* are implicated in LOS  
73 biosynthesis<sup>14,21-23</sup>. In this report we uncover the mechanisms underlying the S-to-R  
74 morphology change of tubercle bacilli and explore the biological consequences with emphasis  
75 on the patho-evolution of *M. tuberculosis*.

76

## 77 **RESULTS**

### 78 **Genome comparison of *M. canettii* S- and R-variants**

79 During passaging of different smooth *M. canettii* strains, we observed spontaneous R-  
80 morphotype variants for two *M. canettii* strains (I and K). These R-variants were re-passaged  
81 three times on solid medium to ensure stable phenotypes and subjected to Illumina-based  
82 WGS. The results obtained pointed to morphotype-linked alterations in the *pks5* locus of *M.*  
83 *canettii* S/R variants (Supplementary Tables 1 and 2, Supplementary Note), which was of  
84 particular interest given suggested roles for Pks5 polyketide synthases in morphotype changes  
85 and LOS production in different mycobacterial species<sup>14,21</sup>. In the LOS-producers *M.*  
86 *marinum*<sup>24</sup> and *M. kansasii*<sup>25</sup>, the Pks5-encoding locus harbours two proximal *pks5* homologs  
87 separated by one or more interspaced *pks5*-associated gene(s) (Fig. 1A). The genome of *M.*  
88 *canettii* STB-A<sup>3</sup> also shows a twin-*pks5* configuration similar to *M. marinum*. In contrast *M.*  
89 *tuberculosis*, which does not produce LOS only has a single *pks5* and lacks a full-length *pap*  
90 ortholog (Fig. 1A).

91

### 92 **Recombination of two *pks5* genes in *M. canettii* K<sub>R</sub> and *M. tuberculosis***

93 To characterize the *pks5* locus in strains I<sub>S/R</sub>, K<sub>S/R</sub> and *M. tuberculosis* H37Rv we performed  
94 long-range PCR using *pks5*-flanking primers, yielding amplicons of ca. 15 kb for both the S-  
95 and R-variants of strain I, and 6 kb for *M. tuberculosis* H37Rv, corresponding to the twin- and  
96 single-*pks5* configuration, respectively (Fig. 1 A, B). For strain K, however, the prevalent  
97 amplicon size of the S-variant was 15 kb, while the size for the R-variant was 6 kb, which was  
98 surprising because the previously released STB-K genome sequence assembly<sup>3</sup> indicated only  
99 a single *pks5*. The PCR result suggests that the previous WGS-based genome assembly of  
100 strain K (NC\_019951) contained a misassembly in that region probably due to high sequence  
101 identity (> 94 %) between the two *pks5* genes. Similarly, we also confirmed the presence of  
102 two *pks5* genes by long-range PCR amplicon-sequencing for *M. canettii* strains D and J, for  
103 which previously only one *pks5* was indicated in the released genome sequences NC\_019950

104 and NC\_019952, respectively (Supplementary Fig. 1). Hence, the results obtained for S- and  
105 R-variants of strain K suggest that K<sub>S</sub> contains two *pks5* genes, flanking a gene (*pap*) coding  
106 for a putative polyketide-synthase-associated acyltransferase<sup>26</sup>, whereas K<sub>R</sub> only harbours a  
107 single *pks5* and no interspaced *pap* gene.

108 These findings were supported by results obtained by alignment to the reference  
109 sequences of *M. canettii* STB-A and *M. tuberculosis* H37Rv (Supplementary Fig. 2 and  
110 Supplementary Note). This analysis suggested that homologous recombination in strain K<sub>R</sub>  
111 occurred at a site that left intact the typical polyketide-synthase domain structures of Pks5<sup>26,27</sup>  
112 (Fig. 1). The observed *pks5* configuration in K<sub>R</sub> can thus serve as a model for the situation  
113 found in *M. tuberculosis*, where two former *pks5* genes also seem to have coalesced into a  
114 single *pks5* gene. In the latter case, the proposed recombination event also left the domain  
115 organisation of Pks5 intact, although the site of recombination was apparently different from  
116 the site observed for K<sub>R</sub> (Fig. 1 and Supplementary Fig. 2B). Further comparisons among  
117 different MTBC members<sup>9</sup> showed > 99.93% sequence identity of the single *pks5* gene in  
118 these strains, suggesting a unique recombination event in the most recent common ancestor of  
119 the MTBC after the separation from an *M. canettii*-like progenitor.

120 Finally, for strain I, amplicon-sequencing of the *pks5* locus of I<sub>R</sub> and I<sub>S</sub> confirmed the  
121 presence of *pap* and two *pks5* copies in both morphotypes. However, alignment of amplicon-  
122 derived sequences indicated the presence of multiple non-synonymous SNPs in both *pks5*  
123 genes (6 in *pks5-2* and 3 in *pks5-1*) for the R-variant (Supplementary Fig. 3A), which likely  
124 resulted from recombination of the ketosynthase domain regions of the *pks5* copies  
125 (Supplementary Fig. 3B). From these data we predicted that these changes likely caused the  
126 R-morphotype of I<sub>R</sub>.

127

### 128 **Pap and Pks5-2 restore the S-morphotype in *M. canettii***

129 To test if changes in the *pks5* locus were responsible for the S/R variations in *M. canettii*, we  
130 transformed strains K<sub>R</sub> and I<sub>R</sub>, as well as *M. tuberculosis* H37Rv with the integrating cosmid  
131 C9, selected from an *M. canettii* STB-A large-fragment genomic library constructed for this  
132 purpose in pYUB412. This vector integrates into the *attB* site located in the *glyV*-tRNA of  
133 mycobacterial genomes<sup>28</sup>. The 30.5 kb insert of cosmid C9 spans the *pks5* locus of STB-A  
134 (Supplementary Fig. 4). Fig. 2 shows that recombinant *M. canettii* strains I<sub>R</sub>::C9 and K<sub>R</sub>::C9  
135 regained S-morphology that was indistinguishable from their respective S-variants. To refine  
136 the region required for S-morphotype restitution, we isolated a second cosmid, named H6 that  
137 contains full-length *pap* and *pks5-2* but a 3'-truncated *pks5-1* (Supplementary Fig. 4).

138 Transformation of I<sub>R</sub> and K<sub>R</sub> with H6 yielded smooth colonies for both I<sub>R</sub>::H6 and K<sub>R</sub>::H6  
139 (Supplementary Fig. 5A).

140 Complementation with a *pks5-2* single gene expression construct restored an S-  
141 morphotype for strain I<sub>R</sub>::*pks5-2*, but not for K<sub>R</sub>::*pks5-2* (Supplementary Figs. 5B and 5C).  
142 Moreover, transformation with *pap* was unable to restore smooth colonies in either of the  
143 strains despite appropriate protein expression (Supplementary Figs. 5B and 5D). Together, the  
144 complementation experiments suggest that *pks5-2* and *pap* are necessary for the S-  
145 morphotype in *M. canettii*.

146 In contrast, R-morphology of *M. tuberculosis* H37Rv remained unchanged upon  
147 transformation with cosmid C9 (Fig. 2A) despite correct genomic integration of the cosmid  
148 (Fig. 3). Similarly, transformation of other MTBC lineage members with C9 did not yield S-  
149 morphotypes (Supplementary Fig. 6). These results suggest that apart from an appropriate  
150 *pks5-pap* locus, additional genes intervene in the formation of S-morphotypes in tubercle  
151 bacilli.

152

### 153 ***M. canettii* strains synthesize LOS**

154 Analysis of total lipid extracts from a large panel of *M. canettii* strains by thin-layer  
155 chromatography (TLC) showed glycoconjugate spots, with TLC mobilities similar to that of  
156 LOS from *M. canettii* reference strain CIPT-140010059 (STB-A or *M. canettii* strain A)<sup>29</sup> in  
157 all tested strains. Substantial differences in the quantity produced by each strain were  
158 observed (Fig. 4A). In contrast, no such glycoconjugates were detected in *M. tuberculosis*  
159 H37Rv, consistent with the long-standing knowledge that *M. tuberculosis* does not synthesize  
160 LOS (Fig. 4A)<sup>30</sup>. Purification and MALDI-TOF mass spectrometry analysis of LOS from *M.*  
161 *canettii* strains A, K<sub>S</sub> and I<sub>S</sub> revealed pseudomolecular-ion mass peaks at *m/z* 2530, 2572, and  
162 2614 for LOS from strain K<sub>S</sub> (Fig. 4B) and strain A<sup>29</sup>, whereas the pattern of strain I<sub>S</sub> showed  
163 peaks at *m/z* 2516, 2558 and 2600 (Fig. 4B), consistent with the different mobility on TLC  
164 (Figs. 4A and 4C). The 14 mass-unit difference indicates strain-specific structural differences,  
165 likely due to the absence of one methyl-group from the carbohydrate or the lipid moiety.

166 The structure of the simplest carbohydrate domain of the *M. canettii* LOS is 2-O-Me-  
167 α-L-Fucp(1->3)-β-D-Glcp(1->3)-2-O-Me-α-L-Rhap(1->3)-2-O-Me-α-L-Rhap(1->3)-β-D-  
168 Glcp(1->3)-4-O-Me-α-L-Rhap(1->3)-6-O-Me-α-D-Glc(1<->1)-tri-O-acyl-α-D-Glc (Fig. 4D).  
169 This octaglycosyl unit is usually further glycosylated by an incompletely defined *N*-acyl  
170 derivative of a 4-amino-4,6-dideoxy-Galp residue to generate a second nonasaccharide-  
171 containing glycolipid (LOS 9) (Fig. 4D)<sup>29</sup>. The MALDI-TOF mass spectra of LOS purified

172 from strains K and A are consistent with the LOS 9 structure. Of note, similar patterns of ion  
173 mass peaks were detected in spectra of LOS purified from *M. canettii* strains D, E, F, G, L,  
174 and H, while LOS of strain J showed a 14 mass difference, similar to strain I<sub>S</sub> (Supplementary  
175 Fig. 7).

### 176 **Rough *M. canettii* variants I and K are deficient in LOS biosynthesis**

177 Having established that all tested *M. canettii* strains synthesized LOS, we next compared the  
178 production of these glycoconjugates in the R-variants of I and K. As predicted, I<sub>R</sub> was  
179 severely impaired in LOS production with only trace amounts detected, and LOS was  
180 undetectable in K<sub>R</sub> (Fig. 4C and Supplementary Fig. 8). No other differences in polyketide-  
181 derived-lipids were observed between the S- and R-variants (Supplementary Fig. 9).  
182 Complementation with cosmid C9 restored LOS biosynthesis in recombinant I and K strains  
183 (Fig. 4C), whereas recombinant expression of *pks5-2* alone restored the LOS profile in  
184 I<sub>R</sub>::*pks5-2*, but not in K<sub>R</sub>::*pks5-2* (Supplementary Fig. 10A), likely due to the absence of full-  
185 length *pap* in K<sub>R</sub>::*pks5-2*. Indeed, based on current knowledge on acyl-trehalose biosynthesis  
186 in *M. tuberculosis*<sup>31,32</sup>, a *pap*-encoded acyltransferase is needed to catalyze the transfer of  
187 Pks-produced polymethyl-branched fatty acids onto trehalose.

188 We also tested LOS production in the MTBC strains complemented with cosmid C9,  
189 despite unaffected R-morphotype. LOS was not detected in any of the recombinant *M.*  
190 *tuberculosis* strains (Supplementary Fig. 10B), suggesting that apart from *pks5* recombination  
191 and *pap* deletion, in the MTBC additional loss-of-function mutations or insertions/deletions  
192 (indels) have occurred in adjacent genes of the LOS-encoding locus that are not covered by  
193 cosmid C9 (Supplementary Tables 3 and 4). These results establish that point mutations or  
194 recombination/deletion events in the core *pks5-pap* locus of *M. canettii* strains I<sub>R</sub> and K<sub>R</sub> led  
195 to LOS deficiency and R-morphology. The results also explain the R-morphotype of *M.*  
196 *tuberculosis* and open new perspectives for detailed research on the functions of *pks5*-  
197 adjacent genes.

198

### 199 **Increased fitness and virulence of R-variants in cellular and animal models**

200 Given the identified altered cell surface structure associated with S/R morphology, the  
201 question arose whether these changes had an impact on host-pathogen interactions. We thus  
202 undertook a series of infection experiments, starting with tests of intracellular replication, a  
203 hallmark of mycobacterial virulence. Differentiated human THP-1 macrophages were infected  
204 with Sauton-grown *M. canettii* strains K<sub>S</sub>, K<sub>R</sub> and K<sub>R</sub>::C9, as well as K<sub>R</sub>::vector-control, up to



205 five days. While no intracellular growth was observed for  $K_S$  and  $K_R::C9$ , the R-morphotypes  
206  $K_R$  and  $K_R::$ vector-control replicated readily, analogous to *M. tuberculosis* H37Rv (Figs. 5A  
207 and 5B). Similar results were obtained when human peripheral blood monocyte-derived  
208 macrophages from healthy donors were infected with the different morphotypes  
209 (Supplementary Fig. 11A), confirming that the increased fitness advantage of the R-  
210 morphotypes was a general phenomenon in human macrophages and not just in THP-1 cells.  
211 For murine-derived RAW macrophages a similar trend, but without significant difference was  
212 observed (Supplementary Fig. 11B).

213 To test whether an increased fitness advantage could also be observed *in vivo*, we first  
214 infected SCID mice intravenously with  $1 \times 10^6$  CFU of each morphotype. Mice infected with  
215 *M. tuberculosis* H37Rv or *M. canettii*  $K_R$  had a median survival of 16 and 24 days pi,  
216 respectively, while mice infected with strains  $K_S$  and  $K_R::C9$  had a longer survival time; on  
217 average 31 and 36 days, respectively (Fig. 5C). Higher virulence of R-morphotypes was also  
218 observed in the sensitive guinea pig model, using low-dose aerosol infection (Fig. 5D). While  
219 in this highly susceptible model, the S-variants of *M. canettii* were already substantially  
220 virulent and able to replicate in infected animals, the ratios of the bacterial burden in the lungs  
221 at day 42 relative to day 1 were significantly higher for strain  $K_R$  than those for the S-  
222 morphotypes. Interestingly, for animals infected with  $K_R::C9$  (Fig. 2) we observed more than  
223 half of the colonies showing a re-converted R-morphotype, which was never observed in any  
224 of our previous *in vitro* experiments, suggesting possible reversion of the usually very stable  
225 pYUB412-based integrated genetic complementation<sup>33</sup>, due to *in vivo* fitness advantages of R-  
226 morphotypes during the long-duration *in vivo* infection assays.

227 To further investigate the host-pathogen interaction of S- and R-variants, we  
228 characterized the inflammatory responses induced in infected phagocytes, as recently  
229 performed for S- and R-forms of *M. abscessus*<sup>34,35</sup>. As shown in Figs. 5E and 5F, a potential  
230 LOS-dependent anti-inflammatory effect was observed in *M. canettii*-infected bone-marrow  
231 derived dendritic cells (BM-DCs) of C57BL/6 mice. Strains  $K_S$  and  $K_R::C9$  induced  
232 significantly lower secretion of NF- $\kappa$ B-dependent inflammatory cytokines IL-6 and IL-12p40  
233 than  $K_R$ . Results with these two cytokines, known to be induced in response to infection with  
234 *M. tuberculosis*<sup>36</sup>, were also representative for TNF- $\alpha$  and NF- $\kappa$ B-dependent CCL5 and  
235 CXCL10 chemokines (Supplementary Fig. 12). In our experimental conditions, most of the  
236 responses were dependent on interaction via Toll-like receptor 2 (TLR-2). Smooth variants  
237 showed reduced interaction with this crucial innate immune sensor of numerous  
238 mycobacterial ligands (Figs. 5 G, 5H and Supplementary Fig. 13). Presence or absence of

239 LOS thus seems to strongly influence the complex pattern of host-tubercle bacilli interaction,  
240 with likely consequences for virulence and pathogenesis.

241

## 242 **DISCUSSION**

243 The evolutionary transition for a bacterial population from low-virulence/high genetic  
244 diversity towards high-virulence/low genetic diversity is well established for some major  
245 human pathogens such as *Yersinia pseudotuberculosis* vs *Yersinia pestis* or *Salmonella*  
246 *enteritidis* vs *Salmonella typhi*<sup>37</sup>. In contrast, the specific genetic changes that led to the  
247 emergence of *M. tuberculosis* are less well understood. Here we have exploited the ancestral-  
248 state characteristics of *M. canettii* to address this gap in our knowledge<sup>3,6,9</sup>. We show that the  
249 transition of *M. tuberculosis* from likely generalist to obligate pathogen was associated with a  
250 dramatic change in mycobacterial surface glycolipid composition. The S-to-R morphotype  
251 variation we have studied here has been linked with higher virulence in opportunistic  
252 pathogenic mycobacteria<sup>11-14</sup> and variation in LOS content has been shown to account for  
253 morphology differences in *M. kansasii*<sup>13</sup> or *M. marinum*<sup>14,18,19</sup>. However, earlier studies on *M.*  
254 *canettii* colony morphology have provided inconclusive results. While a study from van  
255 Soolingen and coworkers found differences in LOS content between S/R colony variants of  
256 an *M. canettii* strain isolated from a 2-year-old Somali child<sup>4</sup>, Lemassu and colleagues did not  
257 observe a correlation between LOS content and colony morphology in various strains tested<sup>20</sup>,  
258 likely because the used strains were poor LOS producers with intermediate morphotypes. In  
259 this current work we resolve these ambiguities and clearly link LOS biosynthesis with the  
260 smooth colony morphotype. We also provide a genetic mechanism for the phenotype that  
261 helps explain the evolution of the tubercle bacilli. Our results indicate that recombination of  
262 two *pks5* genes associated with deletion of the interspersed *pap* gene evidently was a  
263 molecular event that became fixed in the most recent common ancestor of the MTBC after the  
264 phylogenetic separation from the *M. canettii* clade (Fig. 6). Indeed, while *M. canettii* strains  
265 possess a twin *pks5* and *pap* conformation and synthesize LOS, all members of the classical  
266 MTBC contain an abridged *pks5* locus missing a full length *pap* gene and do not produce  
267 LOS. Identification of a similar recombination event in a spontaneous R-variant of *M. canettii*  
268 K reinforces the likelihood of this evolutionary scenario. Comparable recombination-deletion  
269 events also occurred for other genes, e.g. *pknH* (Supplementary Note).

270 Pks5 is a type-I polyketide synthase and a member of the broader polyketide-synthase  
271 family, which in mycobacteria have important functions that range from catalyzing the  
272 essential last condensation step of mycolic acid biosynthesis (Pks13)<sup>38</sup> to the synthesis of the

273 polyketide backbone of phenolic glycolipids (Pks15/1)<sup>39</sup> or the synthesis of mycoketides  
274 (Pks12)<sup>40</sup>. In *M. marinum*, the two Pks5 polyketide synthases (Pks5 and Pks5.1) are thought  
275 to be involved in the synthesis of polymethyl-branched fatty acids, which are further modified  
276 by glycosyltransferases and methyltransferases encoded by genes adjacent to the *pks5*  
277 genes<sup>22,23,41</sup> to produce LOS. Indeed, disruption of *pks5* (*MMAR\_2340*), analogous to  
278 disruptions of the adjacent genes *fadD25* (*MMAR\_2341*), *papA4* (*MMAR\_2343*), and *papA3*  
279 (*MMAR\_2355*) leads to a complete loss of LOS, suggesting that besides the core *pks5-pap*  
280 locus, several flanking genes are also involved in the early steps of LOS-  
281 biosynthesis<sup>14,18,19,22,23,41,42</sup> (Supplementary Table 3).

282 Within the group of tubercle bacilli, the overall genetic organization of the  
283 orthologous LOS locus is similar between *M. canettii* and the non-functional version in *M.*  
284 *tuberculosis*. However, apart from the recombined *pks5* and the deleted *pap* gene, several  
285 flanking genes show SNPs and small indels (Supplementary Table 4), some of which might  
286 represent loss-of-function mutations involved in the non-complementation phenotype with  
287 cosmid C9 in MTBC members. These findings suggest that after the phylogenetic separation  
288 of the MTBC from the *M. canettii*-like progenitor pool, in addition to *pks5* recombination and  
289 *pap* deletion, other mutations in genes of the LOS locus accumulated in the MTBC in the  
290 absence of selective pressure for sustaining LOS biosynthesis. While LOS production might  
291 play an important role in generalist mycobacteria, it appears that its absence might provide a  
292 selective advantage for specialized pathogens in the mammalian host.

293 This conclusion is supported by our different infection experiments, where loss of  
294 LOS by *M. canettii* R-variants led to increased virulence in human macrophages and under *in*  
295 *vivo* conditions, particularly for the sensitive guinea pig infection model. These data support a  
296 scenario wherein the recombination of *pks5* genes in a common ancestor of the MTBC has  
297 contributed to the evolutionary success and host adaptation of the resulting LOS-deprived  
298 strains. This finding is in agreement with data for other mycobacterial species, where  
299 increased virulence of R-morphotypes relative to S-morphotypes has been reported<sup>11,12,14</sup>,  
300 although the involved glycolipids are different. In *M. avium*, for example, homologous  
301 recombination within the *ser2* gene cluster likely led to phenotype changes linked to loss of  
302 GPLs<sup>43</sup>. For *M. abscessus*, a masking effect of GPLs on the outermost layer of the cell wall  
303 of the S-morphotype strains has been suggested, which was related to repression of TLR2  
304 responses<sup>34</sup>. Similarly, LOS is located in the outermost layer of the mycobacterial cell  
305 envelope<sup>44</sup> and thus might be interacting with other cell wall-associated  
306 lipids/glycoconjugates such as phthiocerol dimycocerosates, lipoarabinomannans or the 19-

307 kD lipoprotein<sup>45</sup>, which are important for host-pathogen interaction<sup>46</sup>. At present, it is difficult  
308 to speculate by which mechanisms R-variants of tubercle bacilli might have gained a fitness  
309 advantage during infection. However, differences we show here in TLR2-mediated  
310 inflammatory responses between S- and R-variants of *M. canettii* K suggest that bacterial  
311 surface remodelling could well have played an important role in the ancestor of the MTBC  
312 during adaptation to mammalian hosts. In this respect, the proposed recombination of *pks5*  
313 and deletion of *pap* in a common ancestor of the MTBC adds to previously described  
314 differences between *M. canettii* and the MTBC, such as the putative loss of vitamin B12  
315 production due to the *cobF* deletion<sup>3,7,9,47,48</sup>, the integration of gene *pe\_pgrs33* (*rv1818c*)<sup>3</sup>, the  
316 molecular scars in *pks8/17* and three other gene pairs<sup>3,7,9</sup>, or the exchange of the exotoxin-  
317 encoding domain in CpnT (Rv3903)<sup>9,49</sup> (Fig. 6). While these reported differences are mainly  
318 based on hypotheses formulated during comparative genomics and genome analysis  
319 approaches, the virulence differences observed for rough *M. canettii* relative to isogenic LOS-  
320 producing smooth *M. canettii* strains now provide first experimental support of our postulated  
321 evolutionary model (Fig. 6). Recombination of two ancestral *pks5* genes and consequent  
322 remodelling of the bacterial cell surface thus represent key events in the emergence of the  
323 professional pandemic pathogen *M. tuberculosis*.

324 **Authors to whom correspondence and requests for materials should be addressed:**

325 Roland Brosch (roland.brosch@pasteur.fr) or Christophe Guilhot  
326 ([Christophe.Guilhot@ipbs.fr](mailto:Christophe.Guilhot@ipbs.fr))

327 **Acknowledgements**

328 We thank Torsten Seemann for initial help with NeighborNet analysis, and Hannes Pouseele  
329 for help with mapping and SNP analysis. We are also grateful to Ida Rosenkrands and  
330 Giovanni Delogu for kindly providing polyclonal anti-SigA antibodies and vector pMV10-25,  
331 respectively, and Karim Sébastien for expert assistance in animal care in biosafety-A3  
332 facilities. We acknowledge the support by the European Community's grant 260872, the EU-  
333 EFPIA Innovative Medicines Initiative (grant 115337), the Agence Nationale de Recherche  
334 (ANR-14-JAMR-001-02) and the Fondation pour la Recherche Médicale FRM  
335 (DEQ20090515399 and DEQ20130326471). High-throughput sequencing was performed on  
336 the Genomics Platform, member of the "France Génomique" consortium (ANR10-INBS-09-  
337 08). R.B. is a member of the LabEx consortium IBEID at the Institut Pasteur. F. L-C was  
338 supported by the French Region Ile-de- France (Domaine d'Intérêt Majeur Maladies

339 Infectieuses et Emergentes) PhD program. E.C.B. was supported by a stipend from the  
340 Pasteur–Paris University (PPU) International PhD program and the Institut Carnot Pasteur  
341 Maladies Infectieuses.

342

### 343 **Author contributions**

344 E.C.B., C.G., L.M. and R.B. designed the study. E.C.B., W.F., F.L.C., and A.P. performed  
345 mycobacterial phenotypic assays and/or infection experiments. E.C.B., A.C. and R.B.  
346 established genetic constructs. W.M., G.E., F.L., M.D. and C. G. generated and/or analysed  
347 mycobacterial lipid and lipooligosaccharide profiles. E.C.B., L.Ma, C.B., M.O., T.P.S. and  
348 P.S. generated and/or analysed sequence data. E.C.B and L.Majlessi conducted and analysed  
349 immune assays. E.C.B., T.P.S., P.S., C.G. and R.B wrote the manuscript, with comments  
350 from all authors.

351

### 352 **Competing financial interests**

353 P.S. is a consultant for Genoscreen. All other authors declare no competing financial interests.

354

### 355 **Accession codes**

356 The WGS-generated reads of the *M. canettii* I<sub>S/R</sub> and K<sub>S/R</sub> strains were deposited in the  
357 European Nucleotide Archive (ENA) under accession number PRJEB11645 (ERP013045).

358

359

### 360 **Figure legends**

361

362 **Fig. 1.** Comparison of *pks5* genomic region of various mycobacterial strains. (A) *pks5* genetic  
363 region of *M. kansasii* ATCC 12478, *M. marinum* M, *M. canettii* A and *M. tuberculosis*  
364 H37Rv. Percentages on gray lines represent identity values as defined by ClustalW2 between  
365 genes of *M. kansasii*, and *M. marinum* or *M. canettii* A and *M. marinum* or *M. tuberculosis*  
366 H37Rv. The red arrows indicate location of primers used for long range PCR of *pks5* gene(s)  
367 in *M. canettii* strains I and K, as well as in *M. tuberculosis* H37Rv. (B) Results of long range  
368 PCR using above-mentioned primers that bind outside the *pks5* genes. *M. tuberculosis* H37Rv  
369 (*Mtb*); *M. canettii* strains: I<sub>S</sub>, I<sub>R</sub>, K<sub>S</sub> and K<sub>R</sub>. Note that for strains I<sub>S</sub> and I<sub>R</sub> unspecific  
370 fragments at ~ 12 kb are visible. Data are representative of at least three repetitions. (C)  
371 Genetic locus of *pks5* genes in *M. canettii* strains K<sub>S</sub> and K<sub>R</sub> and potential recombination  
372 region in K<sub>R</sub> (depicted by black arrows). Percentages on gray lines represent identity values as  
373 defined by ClustalW2. (D) Domain organization of the *pks5* genes of *M. canettii* strains K<sub>S</sub>

374 and K<sub>R</sub>. Domains were predicted according to the organization of *pks5* of *M. tuberculosis*  
375 H37Rv<sup>50</sup> and their respective amino acid positions (AA) are depicted either above or below  
376 the particular domains. Sequences of individual domains of *pks5-1* and *pks5-2* were aligned  
377 using ClustalW2 and identity values are shown as percentage. Origin of the domains of the  
378 recombinant *pks5* of *M. canettii* strain K<sub>R</sub> is represented in different nuances of gray (light  
379 gray originating from *pks5-2* and dark gray from *pks5-1*; medium gray indicates that domains  
380 are identical between *pks5-1* and *pks5-2*). Domain abbreviations: ketosynthase (KS),  
381 acyltransferase (AT), dehydratase (DH), enoylreductase (ER), ketoreductase (KR) and acyl-  
382 carrier protein (ACP).

383

384 **Figure 2.** Complementation of morphology phenotypes of R variants. (A) Colony  
385 morphologies of *M. canettii* strains K<sub>S</sub> and I<sub>S</sub> and their rough mutants K<sub>R</sub> and I<sub>R</sub>  
386 complemented with the whole *pks5* locus (C9) as well as *M. tuberculosis* H37Rv WT and *M.*  
387 *tuberculosis*::C9. Data are representative of at least ten repetitions (plating). Scale bar = 2.5  
388 mm. (B) *M. canettii* strains K<sub>S</sub>, K<sub>R</sub> and K<sub>R</sub>::C9 grown in 7H9 medium supplemented with  
389 ADC. Data are representative of at least ten repetitions. Scale bar = 5.0 mm. (C) Ziehl-  
390 Neelsen staining of *M. canettii* strains K<sub>S</sub>, K<sub>R</sub> and K<sub>R</sub>::C9. Data are representative of 2  
391 repetitions. Scale bar = 10 μm.

392

393 **Figure 3.** PFGE and Southern hybridization analyses with PCR-derived probes binding either  
394 in a conserved domain of *pks5* (middle panel) or within the *pap* gene (right panel). Genomes  
395 of strains were digested with *MfeI*, resulting in either a 20 or a 12 kb fragment (black arrows).  
396 For all C9-complemented strains, the probe hybridized twice, with fragments of 20 kb and 12  
397 kb confirming the presence of the natural and the vector-integrated *pks5* loci. PFGE gels were  
398 run for 16 h with a pulse of 1 s; *M. canettii* A; *M. tuberculosis* H37Rv (*Mtb*); *M. canettii*  
399 strains K<sub>S</sub>, K<sub>R</sub>, K<sub>R</sub>::C9; K<sub>R</sub>::vector-control; *M. tuberculosis* H37Rv::C9; cosmid C9; M: low-  
400 range PFG Marker (NEB). Data are representative of three repetitions.

401

402 **Figure 4.** Deficient LOS production in rough morphotypes. (A) TLC analysis of lipid extracts  
403 from various *M. canettii* strains and *M. tuberculosis* H37Rv. Lipid extracts were dissolved in  
404 CHCl<sub>3</sub> and run in (CHCl<sub>3</sub>:CH<sub>3</sub>OH:H<sub>2</sub>O, 60:24:2). Glycolipids were visualized by spraying  
405 with anthrone, followed by charring. Insert corresponds to an enhanced contrast picture  
406 showing a faint blue spot corresponding to LOS in *M. canettii* A. This experiment was  
407 performed at least twice with similar results. (B) MALDI-TOF mass spectra of purified LOS

408 from *M. canettii* strains I<sub>S</sub> and K<sub>S</sub>. Note that the mass peak distribution for the LOS  
409 component of strain I was 14 mass-units lower than that observed for K and A. Further  
410 MS/MS fragmentation analysis showed successive losses of the O-methyl acylated trehalose  
411 and oligosaccharides from the 3 major precursor-ions for strain I, and thus suggests that the  
412 difference of 14 mass-units resulted from the presence of a rhamnosyl unit in LOS of strain I,  
413 instead of a 2-O-Me-rhamnosyl residue linked to the  $\beta$ -glucosyl unit (L-Rhap- $\alpha$ 1->3-D-Glcp-  
414  $\beta$ 1->3) present in LOS of strains K. (C) TLC analysis (CHCl<sub>3</sub>:CH<sub>3</sub>OH:H<sub>2</sub>O, 60:24:2) of lipid  
415 extracts of *M. canettii* strains I<sub>S</sub>, I<sub>R</sub>, I<sub>R</sub>::vector-control, I<sub>R</sub>::C9, as well as K<sub>S</sub>, K<sub>R</sub>, K<sub>R</sub>::vector  
416 control, K<sub>R</sub>::C9 and *M. tuberculosis* H37Rv::C9. This experiment is representative of two  
417 experiments performed independently. LOS = lipooligosaccharide. (D) Structure of  
418 lipooligosaccharides (LOS) from *M. canettii*. The acyl substituents, primarily 2L-,4L-  
419 dimethylhexadecanoate, 2L-,4L-,6L-,8L-tetramethyloctadecanoate, and 2-methyl-3-  
420 hydroxyeicosanoate, are at positions 2,3,6 and 3,4,6 of the terminal glucosyl unit<sup>29</sup>.

421

422 **Figure 5.** Survival of morphotypes in different infection models. (A-B) Intracellular growth  
423 of *M. tuberculosis* H37Rv, *M. canettii* strains K<sub>S</sub>, K<sub>R</sub>, K<sub>R</sub>::C9 and K<sub>R</sub>::vector-control in  
424 differentiated THP-1 macrophages. THP-1 cells were infected with various strains at an MOI  
425 of 0.05 (~ 1 bacterium per 20 cells). CFU of intracellular bacteria were determined 3 h and 3,  
426 4 and 5 days post infection (pi). The figure shows CFU numbers (A) and fold growth rates  
427 (B). Data are represented as means and standard deviation of at least four independent  
428 experiments. Significance in difference was determined using Two-way ANOVA (\**p* < 0.05,  
429 \*\**p* < 0.001, \*\*\**p* < 0.0001). (C) Survival of SCID mice infected with different morphotypes.  
430 1 x 10<sup>6</sup> CFU per mouse of *M. tuberculosis* H37Rv, *M. canettii* strains K<sub>S</sub>, K<sub>R</sub> or K<sub>R</sub>::C9 were  
431 IV-injected and survival of mice was monitored. Endpoints were defined as loss of > 20 % of  
432 body weight. The initial dose of all strains was comparable with 4.6 x 10<sup>6</sup> CFU/ml for  
433 H37Rv, 3.6 x 10<sup>6</sup> CFU/ml for K<sub>S</sub>, 4.1 x 10<sup>6</sup> CFU/ml for K<sub>R</sub> and 3.3 x 10<sup>6</sup> CFU/ml for K<sub>R</sub>::C9.  
434 Data represent one experiment with 10 mice per group. (D) Bacterial load of morphotypes in  
435 lungs of infected guinea pigs. Guinea pigs were infected via aerosol route with 2.5x10<sup>6</sup> CFU.  
436 Lungs of infected animals were homogenized at day 1 and day 42 pi and CFU of different  
437 morphotypes were determined. Data represent median with interquartile range of CFU at day  
438 42 divided by CFU at day 1 of two biological replicates with 4 guinea pigs per group (strains  
439 K<sub>S</sub> and K<sub>R</sub>) or 1 experiment with 4 guinea pigs per group (K<sub>R</sub>::C9). Significant difference was  
440 observed using Kruskal-Wallis test with Dunn's correction (\**p* < 0.05, \*\**p* < 0.01). (E-F) IL-6  
441 and IL-12p40 production in BM-DCs upon infection with different morphotypes. BM-DCs of

442 C57BL/6 WT were infected with Sauton-grown *M. tuberculosis* H37Rv, *M. canettii* strains  
443 K<sub>S</sub>, K<sub>R</sub> or K<sub>R</sub>::C9 at an MOI of 1. 24 h pi, levels of IL-6 and IL-12p40 in the cell supernatants  
444 were determined by ELISA. Note that a dominant inhibitory effect of LOS on the induction of  
445 inflammatory responses was excluded since co-infection of BM-DCs with strains K<sub>S</sub> and K<sub>R</sub>  
446 did not result in less cytokine production than infection with *M. canettii* K<sub>R</sub> alone. Data are  
447 represented as means and standard deviation of three independent experiments. Significance  
448 in difference was determined using Mann Whitney test (\**p* < 0.05). (G-H) Differential  
449 interaction of S- and R-morphotypes with TLR2. Human TLR2- or TLR4-transfected  
450 HEK293 cells were incubated with S- and R-morphotypes at an MOI of 1. At 24 h pi, levels  
451 of secreted embryonic alkaline phosphatase reporter gene under the control of NF-κB were  
452 measured with a spectrophotometer. PAM3CSK4 (10 μg/ml) and LPS (100 ng/ml) were used  
453 as positive controls for TLR2- or TLR4-mediated stimulation, respectively. Data are  
454 represented as means and standard deviation of at least three independent experiments.  
455 Significance in difference was determined using Mann-Whitney test (\*\*\**p* < 0.001). n.s. non-  
456 stimulated.

457

458 **Figure 6.** Scheme showing supposed molecular key events in mycobacterial evolution from  
459 the recombinogenic *M. canettii* strain pool of putative environmental origin, towards  
460 professional pathogens of mammalian hosts evolved by clonal expansion of one emerging  
461 sublineage. Network phylogeny inferred among eight *M. canettii* strains used in this study,  
462 and 46 MTBC strains by NeighborNet analysis based on genome sequence data. Gene names  
463 and arrow shown in grey refer to previously described differences between *M. canettii* strains  
464 and MTBC members<sup>9</sup>, whereas the *pks5* recombination event is marked by a red arrow.  
465 Figure adapted from Bottai et al.<sup>1</sup> and Boritsch et al.<sup>9</sup>.

466

467



## 468 **METHODS**

### 469 **Mycobacterial strains and growth conditions**

470 Cloning was performed in LB-grown *Escherichia coli* XL-2 (Stratagene) using hygromycin  
471 (200  $\mu\text{g}\cdot\text{ml}^{-1}$ ) or kanamycin (50  $\mu\text{g}\cdot\text{ml}^{-1}$ ) selection. MTBC and *M. canettii* strains were  
472 grown in Middlebrook 7H9 broth (Becton-Dickinson) containing albumin-dextrose-catalase  
473 (ADC) or on Middlebrook 7H11 medium (Becton-Dickinson) containing oleic acid-albumin-  
474 dextrose-catalase (OADC) or in Sauton medium (when specified) at 37°C. Hygromycin (50  
475  $\mu\text{g}\cdot\text{ml}^{-1}$ ) was used for mycobacterial selection.

476

### 477 **Genome analysis of S/R morphotype isolates**

478 Mycobacterial DNA was prepared by standard procedures<sup>16,17</sup>. After final ethanol  
479 precipitation and washing, DNA was resuspended in TE buffer and used for library  
480 preparation and Illumina-based genome sequencing. This approach yielded on average 21  
481 million ( $I_S$  and  $I_R$ ) and 8 million ( $K_S$  and  $K_R$ ) reads per strain, which were then mapped  
482 against the corresponding reference sequences of STB-I (ENA WGS project  
483 CAO000000000) and STB-K (NC\_019951). Reads were aligned against the reference  
484 genomes<sup>3</sup> using SHRiMP<sup>51</sup>. Alignment maps were visualized with Tablet<sup>52</sup> and SNPs were  
485 called according to coverage sums and variant frequencies. At least 10 reads had to be  
486 matched with a substitution frequency  $> 0.89$  to guarantee the detection of high confidence  
487 SNPs. Additional mapping and SNP analysis was performed using BioNumerics v7.6  
488 software (Applied Maths), using parameters pre-calibrated based on re-sequencing data of  
489 reference genomes<sup>53</sup>.

490

### 491 **Network phylogenic analysis of *M. canettii* and MTBC strains**

492 Network phylogeny among *M. canettii* and MTBC strains was inferred by NeighborNet  
493 analysis, based on pairwise alignments of whole-genome SNP data. Phylogenetic groupings  
494 were identified by split decomposition analysis using the SplitsTree4 software<sup>54</sup>.

495

### 496 **Long-range PCR and *pks5*-sequencing**

497 *pks5* and/or *pap* genes were amplified from chromosomal DNA using Platinum-Taq  
498 polymerase (Life Technologies) according to the manufacturer's manual with primers EB-1  
499 TTTATTAATCAGGGAAAGGCGACATCGGA and EB-2 TTTTATAACCGCCAAGAC  
500 AAACCTTCATC for annealing at 55°C and elongation at 68°C (10 min). Amplicons were  
501 Sanger-sequenced after QIAquick (Quiagen) purification, using primers listed in

502 supplementary Table S5. Amplification of *pks5-1* with the last part of *pap* or amplification of  
 503 *pks5-2* with the first part of *pap* to verify the presence of both *pks5* genes in the various *M.*  
 504 *canettii* strains was performed using Pwo Polymerase (Roche) and the oligos  
 505 EB-3 GACGAACTACTAGTCGTTGGTAGCG and EB-4  
 506 TTTTATAACCGCCAAGACAAACTTCATC, and EB-5  
 507 TTTCAGGGAAAGGCGACATCGGA and EB-6  
 508 TTTCGCTACCAACGACTAGTAGTTCGTC, respectively.

509

### 510 **Complementation of R-variants**

511 R-variants of *M. canettii* strains K and I, as well as *M. tuberculosis* H37Rv and other MTBC  
 512 members were transformed with the integrating cosmid C9 and H6 spanning the extended or  
 513 partial *pks5* locus of *M. canettii* strain A. The C9 and H6 clones were selected from a cosmid  
 514 library that was constructed in pYUB412<sup>28</sup> by using partially-digested, agarose-embedded  
 515 genomic DNA<sup>55,56</sup> of *M. canettii* reference strain CIPT 140010059 (STB-A). Clone-inserts  
 516 were PCR-verified using primers binding in vector- or insert-sequences: (T7-F  
 517 AGGCATGCAAGCTCAGGATA; T7-R GGATCGGTCCAGTAATCGT and T3-F  
 518 GCAGAAGCACTAGACGATCC; T3-R GCCGCAATTAACCCTCACTA). Transformed,  
 519 hygromycin-resistant R-variants that exhibited no S-morphology served as vector-controls.  
 520 Insert-termini sequencing of these latter clones showed partial insert-loss including the *pks5*  
 521 region, whereas genes encoding MCAN\_15411, MCAN\_15421 and part of MCAN 15431  
 522 remained present.

523 For construction of vectors expressing HA-tagged proteins, corresponding genes were  
 524 amplified with Pwo polymerase (Roche). For the construction of the HA-tagged *pks5-2*  
 525 expression plasmid, pTTP1b<sup>57</sup> was cut with *Hind*III (NEB) to remove the kanamycin  
 526 resistance cassette and blunt ends were generated using Klenow fragment (NEB). A  
 527 hygromycin resistance cassette was amplified from pAL70<sup>58</sup> with the oligos AC123  
 528 ACAGGCCTGTCGTCGAGGTCCACCAA and AC124  
 529 ACAGGCCTGGATGCCAGGGCCTTTCA, cut with *Stu*I and cloned into the digested vector  
 530 to generate pAL232. The strong mycobacterial promoter of the gene *hsp60* was amplified  
 531 from chromosomal DNA of *M. tuberculosis* H37Rv with the oligos *Nhe*I\_ *Hind*II\_ *hsp60*\_F  
 532 aaaGCTAGCAAGCTTggtgaccacaacgacgcccgtttgatc and *hsp60*\_ *Spe*I\_ *Eco*RV\_ *Xba*I\_ R  
 533 aaaTCTAGAgatatcACTAGTgtcttggccattgcaagtgattcctcc, the amplified product was cut  
 534 with *Nhe*I and *Xba*I (NEB) and cloned into *Xba*I-digested pAL232 to generate pEB18. The  
 535 gene *pks5-2* was amplified from chromosomal DNA of *M. canettii* strain K<sub>S</sub> with the oligos

536 pks5-2\_SpeI\_F aaaACTAGTGTGGGTAAGGAGAGAACAAAG and pks5-2\_HA\_PsiI\_R  
537 aaaTTATAAttaAGCATAATCAGGAACATCATAACGGATATGAAGGTGCTGCAATGTC  
538 GG. The amplified product was cut with *SpeI* and *PsiI* and cloned into *SpeI-EcoRV* digested  
539 pEB18. For construction of the HA-tagged *pap* expression system, the plasmid pMV10-25  
540 was first cut with *NcoI*, blunt ended using Klenow fragment (NEB) and subsequently cut with  
541 *NheI*. The *pap* gene was amplified using the oligos  
542 *pap\_SpeI\_F* aaaACTAGTGTGATCATTGGCGGGGGC and *pap\_HA\_PsiI\_R*  
543 aaaTTATAAttaAGCATAATCAGGAACATCATAACGGATAGCTAGATACGCGAACTGC  
544 TG. The amplified product was digested with *SpeI* and *PsiI* and cloned into the *NheI*/ blunt  
545 end pMV10-25<sup>59</sup> vector.

546 Whole cell lysates were generated from cultures grown in Middelbrook 7H9 supplemented  
547 with ADC to an OD of 0.6-0.8. Cells were disrupted using a TissueLyser II (Quiagen) and  
548 Zirkonia/ Silica beads (BioSpec) and passed through 0.2 µm filter units. Proteins were  
549 separated on NuPAGE Novex 10% Bis-Tris gels (Invitrogen) for HA-tagged *pap* and  
550 NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen) for HA-tagged *pks5-2*. HA-tagged *pap*  
551 was blotted on a nitrocellulose membrane using an iBlot Dry Blotting System  
552 (LifeTechnologies), while *pks5-2* was blotted on nitrocellulose membranes using a wet  
553 transfer system for 2 h at 100 V at 4°C. Membranes were blocked in 5% milk powder in TBS  
554 and subsequently incubated with either mouse anti-HA (anti-HA.11; Covance) or rabbit anti-  
555 SigA (Statens Serum Institute, Copenhagen, Denmark) primary antibody. Bound antibodies  
556 were detected using a horseradish peroxidase-conjugated sheep anti-mouse or donkey anti-  
557 rabbit (Amersham ECL) antibody and the chemiluminescent signal was developed with a  
558 SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). Image  
559 acquisition was performed with an Azure c300 (Azure Biosystems).

560

### 561 **Ziehl-Neelsen staining**

562 Mycobacteria were grown to an OD of 0.4, smeared on glass slides and killed at 95°C (1 h).  
563 After heat-fixation with 90% ethanol, mycobacteria were stained with carbol-fuchsin and  
564 heated (10 min). After washing, glass slides were incubated with sulphuric acid (25%) (2  
565 min), washed and incubated with 90% ethanol (5 min), washed and counter-stained with  
566 methylene blue (2 min).

567

### 568 **PFGE and Southern Blot hybridization**

569 Genomic DNA in agarose-plugs, prepared as described<sup>55</sup>, was *MfeI*-digested, separated by  
570 pulsed-field gel electrophoresis (Biorad CHEF II, pulse 1 s for 16 h at 6 V·cm<sup>-1</sup>) and  
571 transferred onto Hybond-C-Extra nitrocellulose (GE), as described<sup>55</sup>. Hybridization was  
572 performed with [ $\alpha$ -<sup>32</sup>P]dCTP-labeled PCR-probes at 68°C in 6xSSC/ 0,5% SDS/ 0.01 M  
573 EDTA/ 5xDenhardt's solution/ 100 mg·ml<sup>-1</sup>salmon-sperm DNA. After washing, membranes  
574 were exposed to phosphorimager screens, which were scanned in a STORM phosphorimager.  
575 Probes were amplified from *M. tuberculosis* DNA using *pks5* primers (*pks5*-F  
576 GTTGTGGGAGGCGTTGCT; *pks5*-R GAAACGTCGAACGCATGAC) or from *M. canettii*  
577 K<sub>s</sub> using *pap* primers (*pap*-F CTCGATTATTACGGCTGGT; *pap*-R  
578 CGTATAGCCCGGTGATCAAC).

579

### 580 **Extraction and analysis of lipooligosaccharides**

581 Mycobacterial cells obtained from 7H9-grown cultures were exposed to CHCl<sub>3</sub>/CH<sub>3</sub>OH (1:2,  
582 v/v) for 48h to kill bacteria. Lipids were extracted following previously described  
583 protocols<sup>14,21</sup> and separated by TLC. Finally, glycolipids were visualized by spraying the  
584 plates with a 0.2% anthrone solution (w/v) in concentrated H<sub>2</sub>SO<sub>4</sub>, followed by heating. The  
585 previously described LOS of *M. canettii* strain CIPT 140010059 was used as standard<sup>29</sup>.  
586 Crude lipid extracts were subjected to chromatography on a Sep-Pak Florisil cartridge and  
587 eluted at various concentrations of CH<sub>3</sub>OH (0, 5, 10, 15, 20, 30%) in CHCl<sub>3</sub>. Each fraction  
588 was analyzed by TLC on Silica Gel G60 using CHCl<sub>3</sub>/CH<sub>3</sub>OH/H<sub>2</sub>O (30:12:1, v/v/v) as solvent  
589 and glycolipids were visualized as described above.

590 MALDI-TOF/TOF-MS and MS/MS analyses were conducted in the positive  
591 ionization and reflectron mode by accumulating 10 spectra of 250 laser shots, using the 5800  
592 MALDI TOF/TOF Analyser (Applied Biosystems/Absciex) equipped with a Nd:Yag laser  
593 (349nm). For MS and MS/MS data acquisitions, uniform, continuous, and random stage  
594 motion was selected at a fixed laser intensity of 4000 (instrument-specific units) and 400 Hz  
595 pulse rate and 6000 (instrument-specific units) and 1000Hz, respectively. For MS/MS data  
596 acquisition, the fragmentation of selected precursor-ions was performed at collision energy of  
597 1 kV. Lipid samples were dissolved in chloroform and spotted onto the target plate as 0.5  $\mu$ l  
598 droplets, followed by the addition of 0.5  $\mu$ l matrix solution (10 mg of 2,5-dihydroxybenzoic  
599 acid [Sigma-Aldrich]/ml in CHCl<sub>3</sub>/CH<sub>3</sub>OH, 1/1 [vol/vol]). Samples were allowed to crystallize  
600 at room temperature. Spectra were externally calibrated using lipid standards.

601 Alkaline hydrolysis of purified LOS and total extractable lipids from the various  
602 strains was performed with 1M sodium methanolate for 1h at 37°C. After neutralization with

603 glacial acetic acid, the mixture was dried under stream of nitrogen and lipids were extracted  
604 with diethyl ether and washed twice with water. The resulting fatty acid methyl esters were  
605 converted to trimethylsilyl (TMS) derivatives, using a mixture of  
606 pyridine/hexamethyldisilazane/trimethylchlorosilane (6:4:2, v/v/v).

607 GC-MS analyses were performed using a Thermo TraceGCultra chromatograph  
608 coupled with an ISQ mass spectrometer. Chromatographic separations of the TMS derivatives  
609 of the fatty acid methyl esters were obtained using an Inferno ZB5HT column of 15m. Helium  
610 was the carrier gas at constant flow rate of 1.2mL min<sup>-1</sup>. The oven temperature program was  
611 started at 120°C, ramped to 380°C at 10°C/min (with final isothermal step of 5min at 380°C).  
612 The temperature of the injector was 220°C and injection of 1µl of samples in petroleum ether  
613 was performed in a split mode (ratio of 20:1). EI mass spectra were recorded using electron  
614 energy of 70eV from 60 to 600 with a transfer line maintained at 275°C.

615 To visualize various polyketide-derive lipids, including acyl-trehaloses such  
616 diacyltrehaloses (DAT), polyacyltrehaloses (PAT), sulfolipids (SL), phenolic glycolipids  
617 (PGL) or lipooligosaccharides (LOS) from different *M. canettii* strains metabolic labelling  
618 with <sup>14</sup>C propionate was used. For this TLC analysis, *M. canettii* strains were grown to the  
619 exponential phase in 10 mL 7H9 liquid medium supplemented with ADC and 0.05% Tween  
620 80 and labelled by incubation with 0.4 µCi.ml<sup>-1</sup> [1-<sup>14</sup>C] propionate for 24 h. The TLC plates  
621 were run in CHCl<sub>3</sub>/CH<sub>3</sub>OH/H<sub>2</sub>O (60/16/2) for DAT and SL and CHCl<sub>3</sub>/CH<sub>3</sub>OH (99/1) for  
622 PAT. Labelled lipids were visualized with a Typhoon PhosphorImager (Amersham  
623 Biosciences).

624

### 625 **Macrophage infections**

626 THP-1 (TIB-202D) human monocyte-like cells were purchased from ATCC, directly  
627 amplified and stocked in liquid nitrogen. Only low passage cells (passage number <11) were  
628 used in the experiments. The purchased THP-1 cell line has been authenticated and tested for  
629 microbial contaminants, including mycoplasma, by ATCC. For the experiments, THP-1 were  
630 cultivated in RPMI 1640, GlutaMAX (Life Technologies) containing 10 % heat-inactivated  
631 fetal bovine serum (Life Technologies), seeded at a density of 7.5x10<sup>4</sup> cells per well in 96  
632 well plates and differentiated into macrophages through incubation with 50 mM PMA for 3  
633 days. For infection, bacteria grown in Sauton medium without shaking were sonicated, added  
634 to the macrophages at an MOI of 0.05, (~ 1 bacterium per 20 THP-1 cells) and incubated for 2  
635 h. Sauton medium was used, as it allows the production of more complex polar lipids<sup>18</sup>. After  
636 phagocytosis, 0.1 mg·ml<sup>-1</sup> amikacin was added for 1 h to remove extracellular bacteria and

637 cells were incubated for up to 6 days at 37°C and 5% CO<sub>2</sub>. At various time points  
638 macrophages were lysed with 0.1% Triton-X100 in PBS and lysates plated in serial dilutions  
639 on 7H11+OADC plates to determine intracellular survival of bacteria in CFU. Experiments  
640 were performed as at least four biological replicates, each done in triplicate (technical  
641 replicates).

642 Additional infection experiments were conducted using Raw murine macrophages as  
643 well as Human monocyte-derived macrophages (hMDMs). Raw cells were cultivated in  
644 RPMI 1640 Medium, GlutaMAX (Gibco, Life Technologies) supplemented with 5 % heat-  
645 inactivated fetal bovine serum (Gibco, Life Technologies) and seeded one day before  
646 infection. In parallel, hMDMs were obtained from buffy coats by centrifugation of blood from  
647 healthy human donors in lymphocyte separation medium (Eurobio) and further isolation of  
648 CD14<sup>+</sup> monocytes from the mononuclear cell fraction using CD14 microbeads (Miltenyi  
649 Biotec). Monocytes were differentiated into macrophages in the presence of rhM-CSF (50  
650 ng/ml; R&D Systems). At the day of infection mycobacterial strains grown in Sauton medium  
651 without shaking were sonicated, added to the macrophages at a MOI of 1:20, and incubated  
652 for 2 hrs at 37°C and 5% CO<sub>2</sub>. After phagocytosis, infected macrophages were incubated with  
653 0.1 mg·ml<sup>-1</sup> amikacin for 1 h to remove extracellular bacteria and finally incubated for 6 days  
654 in new RPMI supplemented with 10 % FBS for hMDMs and 1% for Raw cells at 37°C and 5  
655 % CO<sub>2</sub>. At selected time points macrophages were lysed with 0.1 % Triton-X100 in PBS and  
656 bacteria were plated in serial dilutions on 7H11 plates supplemented with OADC to determine  
657 CFU counts. Buffy coats were obtained from healthy donors after informed consent  
658 (Etablissement Français du Sang). Three biological replicates were performed, each done in  
659 triplicate (technical replicates).

660

### 661 **Animal infection studies**

662 Six-week-old female SCID mice (Charles River) were infected intravenously with 200 µl of  
663 5x10<sup>6</sup> bacteria/mouse and survival of mice was monitored. Humane endpoints were defined  
664 as loss of > 20 % of body-weight. The experiment was performed once, using 10 mice per  
665 strain (technical replicates). In a second well-established mycobacterial infection model, five  
666 to six week-old female guinea pigs (Hartley; Charles River) were aerosol-infected using 5 ml  
667 of a suspension containing 5x10<sup>5</sup> bacteria·ml<sup>-1</sup>. Six weeks post-infection, animals were killed  
668 and organs homogenized using a gentleMACS Dissociator (Miltenyi Biotec) and  
669 gentleMACS M tubes. Bacterial loads in organs were determined by plating serial dilutions of  
670 organ homogenates on solid medium. The number of animals included in the experiments

671 (sample size choice) was determined by taking into account the rule of 3Rs (replacement,  
672 reduction, refinement) and statistical requirements. As regards randomization and blinding,  
673 CFU counts were recorded in parallel by different investigators.

674

#### 675 **Cytokine and chemokine assays and HEK-Blue cell reporter assay**

676 ELISA and ProcartaPlex Luminex immunoassay from culture supernatants of infected BM-  
677 DCs was performed as previously described<sup>60</sup>, and/or according to the manufacturer's  
678 instructions (ProcartaPlex Luminex Immunoassay). mAbs specific to IL-12p40 and IL-6 were  
679 from BD Biosciences. Reagents for quantitative ProcartaPlex Luminex immunoassay were  
680 from affymetrix eBioscience. ELISA experiments were performed as three biological  
681 replicates, while Luminex analyses were performed as two independent biological replicates,  
682 each done in duplicate. Signal acquisition was performed on pooled duplicates.

683 HEK-TLR2 and HEK-TLR4 cells (InvivoGen) were grown in DMEM medium (Gibco Life  
684 Technologies) supplemented with 10% FBS, 100  $\mu\text{g}\cdot\text{ml}^{-1}$  Normocin and 1X HEK-Blue  
685 Selection. TLR stimulation assay was performed according to the manufacturer's protocol. 10  
686  $\mu\text{g}\cdot\text{ml}^{-1}$  PAM3CSK4 served as positive control for HEK-TLR2 and 100  $\text{ng}\cdot\text{ml}^{-1}$  LPS as  
687 positive control for HEK-TLR4. Experiments were performed as at least three biological  
688 replicates.

689

#### 690 **Compliance with regulations on animal welfare and ethics**

691 Animal studies were performed in agreement with European and French guidelines (Directive  
692 86/609/CEE and Decree 87-848 of 19 October 1987) after approval by the Institut Pasteur  
693 Safety Committee (Protocol 11.245) and local ethical committees (CNREEA 2012-0061;  
694 CETEA 2013-0036).

695

#### 696 **References:**

- 697 1 Bottai, D., Stinear, T. P., Supply, P. & Brosch, R. Mycobacterial Pathogenomics and  
698 Evolution *Microbiology Spectrum* **2**, MGM2-0025-2013 (2014).
- 699 2 Le Chevalier, F., Cascioferro, A., Majlessi, L., Herrmann, J. L. & Brosch, R.  
700 *Mycobacterium tuberculosis* evolutionary pathogenesis and its putative impact on  
701 drug development. *Future Microbiol.* **9:969-85.**, (2014).
- 702 3 Supply, P. *et al.* Genomic analysis of smooth tubercle bacilli provides insights into  
703 ancestry and pathoadaptation of *Mycobacterium tuberculosis*. *Nat Genet* **45**, 172-179  
704 (2013).
- 705 4 van Soolingen, D. *et al.* A novel pathogenic taxon of the *Mycobacterium tuberculosis*  
706 complex, Canetti: characterization of an exceptional isolate from Africa. *Int J Syst*  
707 *Bacteriol* **47**, 1236-1245. (1997).

708 5 Gutierrez, M. C. *et al.* Ancient origin and gene mosaicism of the progenitor of  
709 Mycobacterium tuberculosis. *PLoS Pathog.* **1**, e5.

710 6 Koeck, J. L. *et al.* Clinical characteristics of the smooth tubercle bacilli  
711 'Mycobacterium canettii' infection suggest the existence of an environmental reservoir.  
712 *Clin Microbiol Infect* **17**, 1013-1019 (2011).

713 7 Blouin, Y. *et al.* Progenitor "Mycobacterium canettii" Clone Responsible for Lymph  
714 Node Tuberculosis Epidemic, Djibouti. *Emerg Infect Dis* **20**, 21-28, (2014).

715 8 Dormans, J. *et al.* Correlation of virulence, lung pathology, bacterial load and delayed  
716 type hypersensitivity responses after infection with different *Mycobacterium*  
717 *tuberculosis* genotypes in a BALB/c mouse model. *Clin Exp Immunol.* **137**, 460-468.  
718 (2004).

719 9 Boritsch, E. C. *et al.* A glimpse into the past and predictions for the future: the  
720 molecular evolution of the tuberculosis agent. *Mol Microbiol.* **93**, 835-852. (2014).

721 10 Panas, M. W. *et al.* Noncanonical SMC protein in *Mycobacterium smegmatis* restricts  
722 maintenance of *Mycobacterium fortuitum* plasmids. *Proc Natl Acad Sci U S A.* **111**,  
723 13264-13271. (2014).

724 11 Kansal, R. G., Gomez-Flores, R. & Mehta, R. T. Change in colony morphology  
725 influences the virulence as well as the biochemical properties of the *Mycobacterium*  
726 *avium* complex. *Microb Pathog* **25**, 203-214, (1998).

727 12 Catherinot, E. *et al.* Hypervirulence of a rough variant of the *Mycobacterium*  
728 *abscessus* type strain. *Infect Immun* **75**, 1055-1058, (2007).

729 13 Belisle, J. T. & Brennan, P. J. Chemical basis of rough and smooth variation in  
730 mycobacteria. *J Bacteriol.* **171**, 3465-3470. (1989).

731 14 van der Woude, A. D. *et al.* Unexpected link between lipooligosaccharide biosynthesis  
732 and surface protein release in *Mycobacterium marinum*. *J Biol Chem* **287**, 20417-  
733 20429, (2012).

734 15 Barrow, W. W. & Brennan, P. J. Isolation in high frequency of rough variants of  
735 *Mycobacterium intracellulare* lacking C-mycoside glycopeptidolipid antigens. *J*  
736 *Bacteriol.* **150**, 381-384. (1982).

737 16 Howard, S. T. *et al.* Spontaneous reversion of *Mycobacterium abscessus* from a  
738 smooth to a rough morphotype is associated with reduced expression of  
739 glycopeptidolipid and reacquisition of an invasive phenotype. *Microbiology* **152**,  
740 1581-1590, (2006).

741 17 Pawlik, A. *et al.* Identification and characterization of the genetic changes responsible  
742 for the characteristic smooth-to-rough morphotype alterations of clinically persistent  
743 *Mycobacterium abscessus*. *Mol. Microbiol.* **90**, 612-629. (2013).

744 18 Burguiere, A. *et al.* LosA, a key glycosyltransferase involved in the biosynthesis of a  
745 novel family of glycosylated acyltrehalose lipooligosaccharides from *Mycobacterium*  
746 *marinum*. *J Biol Chem.* **280**, 42124-42133. (2005).

747 19 Ren, H. *et al.* Identification of the lipooligosaccharide biosynthetic gene cluster from  
748 *Mycobacterium marinum*. *Mol Microbiol* **63**, 1345-1359 (2007).

749 20 Lemassu, A., Levy-Frebault, V. V., Laneelle, M. A. & Daffe, M. Lack of correlation  
750 between colony morphology and lipooligosaccharide content in the *Mycobacterium*  
751 *tuberculosis* complex. *J Gen Microbiol.* **138**, 1535-1541. (1992).

752 21 Etienne, G. *et al.* Identification of the polyketide synthase involved in the biosynthesis  
753 of the surface-exposed lipooligosaccharides in mycobacteria. *J Bacteriol* **191**, 2613-  
754 2621 (2009).

755 22 Nataraj, V. *et al.* MKAN27435 is required for the biosynthesis of higher subclasses of  
756 lipooligosaccharides in *Mycobacterium kansasii*. *PLoS One.* **10**, e0122804. (2015).



- 757 23 Minnikin, D. E. *et al.* in *Tuberculosis - Expanding Knowledge* (ed W. Ribon) Ch. 7,  
758 (InTech, 2015).
- 759 24 Stinear, T. P. *et al.* Insights from the complete genome sequence of *Mycobacterium*  
760 *marinum* on the evolution of *Mycobacterium tuberculosis*. *Genome Res* **18**, 729-741.  
761 (2008).
- 762 25 Wang, J. *et al.* Insights on the Emergence of *Mycobacterium tuberculosis* from the  
763 Analysis of *Mycobacterium kansasii*. *Genome Biol Evol.* **7**, 856-870. doi:  
764 810.1093/gbe/evv1035. (2015).
- 765 26 Quadri, L. E. Biosynthesis of mycobacterial lipids by polyketide synthases and  
766 beyond. *Crit Rev Biochem Mol Biol.* **49**, 179-211. (2014).
- 767 27 Rousseau, C. *et al.* Virulence attenuation of two Mas-like polyketide synthase mutants  
768 of *Mycobacterium tuberculosis*. *Microbiology.* **149**, 1837-1847. (2003).
- 769 28 Bange, F. C., Collins, F. M. & Jacobs, W. R., Jr. Survival of mice infected with  
770 *Mycobacterium smegmatis* containing large DNA fragments from *Mycobacterium*  
771 *tuberculosis*. *Tuber Lung Dis* **79**, 171-180. (1999).
- 772 29 Daffe, M., McNeil, M. & Brennan, P. J. Novel type-specific lipooligosaccharides from  
773 *Mycobacterium tuberculosis*. *Biochemistry.* **30**, 378-388. (1991).
- 774 30 Angala, S. K., Belardinelli, J. M., Huc-Claustre, E., Wheat, W. H. & Jackson, M. The  
775 cell envelope glycoconjugates of *Mycobacterium tuberculosis*. *Crit Rev Biochem Mol*  
776 *Biol.* **49**, 361-399. (2014).
- 777 31 Onwueme, K. C., Ferreras, J. A., Buglino, J., Lima, C. D. & Quadri, L. E.  
778 Mycobacterial polyketide-associated proteins are acyltransferases: proof of principle  
779 with *Mycobacterium tuberculosis* PapA5. *Proc Natl Acad Sci U S A.* **101**, 4608-4613.  
780 (2004).
- 781 32 Bhatt, K., Gurcha, S. S., Bhatt, A., Besra, G. S. & Jacobs, W. R., Jr. Two polyketide-  
782 synthase-associated acyltransferases are required for sulfolipid biosynthesis in  
783 *Mycobacterium tuberculosis*. *Microbiology.* **153**, 513-520. (2007).
- 784 33 Bottai, D. *et al.* Increased protective efficacy of recombinant BCG strains expressing  
785 virulence-neutral proteins of the ESX-1 secretion system. *Vaccine.* **33**, 2710-2718.  
786 (2015).
- 787 34 Rhoades, E. R. *et al.* *Mycobacterium abscessus* Glycopeptidolipids mask underlying  
788 cell wall phosphatidyl-myo-inositol mannosides blocking induction of human  
789 macrophage TNF-alpha by preventing interaction with TLR2. *J Immunol* **183**, 1997-  
790 2007, (2009).
- 791 35 Roux, A. L. *et al.* Overexpression of proinflammatory TLR-2-signalling lipoproteins  
792 in hypervirulent mycobacterial variants. *Cell Microbiol* **13**, 692-704, (2011).
- 793 36 Robinson, R. T., Orme, I. M. & Cooper, A. M. The onset of adaptive immunity in the  
794 mouse model of tuberculosis and the factors that compromise its expression. *Immunol*  
795 *Rev.* **264**, 46-59. (2015).
- 796 37 Achtman, M. Insights from genomic comparisons of genetically monomorphic  
797 bacterial pathogens. *Philos Trans R Soc Lond B Biol Sci* **367**, 860-867 (2012).
- 798 38 Portevin, D. *et al.* A polyketide synthase catalyzes the last condensation step of  
799 mycolic acid biosynthesis in mycobacteria and related organisms. *Proc Natl Acad Sci*  
800 *U S A* **101**, 314-319. (2004).
- 801 39 Constant, P. *et al.* Role of the *pks15/l* gene in the biosynthesis of phenolglycolipids in  
802 the *Mycobacterium tuberculosis* complex. Evidence that all strains synthesize  
803 glycosylated *p*-hydroxybenzoic methyl esters and that strains devoid of  
804 phenolglycolipids harbor a frameshift mutation in the *pks15/l* gene. *J Biol Chem* **277**,  
805 38148-38158, (2002).


- 806 40 Matsunaga, I. *et al.* *Mycobacterium tuberculosis pks12* produces a novel polyketide  
807 presented by CD1c to T cells. *J Exp Med.* **200**, 1559-1569. (2004).
- 808 41 Rombouts, Y. *et al.* Fatty acyl chains of *Mycobacterium marinum*  
809 lipooligosaccharides: structure, localization and acylation by PapA4 (MMAR\_2343)  
810 protein. *J Biol Chem.* **286**, 33678-33688. (2011).
- 811 42 Alibaud, L. *et al.* Increased phagocytosis of *Mycobacterium marinum* mutants  
812 defective in lipooligosaccharide production: a structure-activity relationship study. *J*  
813 *Biol Chem.* **289**, 215-228. (2014).
- 814 43 Eckstein, T. M., Inamine, J. M., Lambert, M. L. & Belisle, J. T. A genetic mechanism  
815 for deletion of the *ser2* gene cluster and formation of rough morphological variants of  
816 *Mycobacterium avium*. *J Bacteriol* **182**, 6177-6182 (2000).
- 817 44 Ortalo-Magne, A. *et al.* Identification of the surface-exposed lipids on the cell  
818 envelopes of *Mycobacterium tuberculosis* and other mycobacterial species. *J Bacteriol*  
819 **178**, 456-461 (1996).
- 820 45 Mortaz, E. *et al.* Interaction of Pattern Recognition Receptors with *Mycobacterium*  
821 *tuberculosis*. *J Clin Immunol* **14**, 14 (2014).
- 822 46 Cambier, C. J. *et al.* Mycobacteria manipulate macrophage recruitment through  
823 coordinated use of membrane lipids. *Nature.* **505**, 218-222. (2014).
- 824 47 Gopinath, K., Moosa, A., Mizrahi, V. & Warner, D. F. Vitamin B(12) metabolism in  
825 *Mycobacterium tuberculosis*. *Future Microbiol* **8**, 1405-1418 (2013).
- 826 48 Young, D. B., Comas, I. & de Carvalho, L. P. Phylogenetic analysis of vitamin B12-  
827 related metabolism in *Mycobacterium tuberculosis*. *Front Mol Biosci.* **2**, 6. (2015)
- 828 49 Danilchanka, O. *et al.* An outer membrane channel protein of *Mycobacterium*  
829 *tuberculosis* with exotoxin activity. *Proc Natl Acad Sci U S A.* **111**, 6750-6755.  
830 (2014).
- 831 50 Delahay *et al.* The coiled-coil domain of EspA is essential for the assembly of the type  
832 III secretion translocon on the surface of enteropathogenic *Escherichia coli*. *J Biol*  
833 *Chem.* **274**, 35969-35974.

## 834 835 **References Methods**


- 836
- 837 51 David, M., Dzamba, M., Lister, D., Ilie, L. & Brudno, M. SHRiMP2: sensitive yet  
838 practical SHort Read Mapping. *Bioinformatics.* **27**, 1011-1012. (2011).
- 839 52 Milne, I. *et al.* Using Tablet for visual exploration of second-generation sequencing  
840 data. *Brief Bioinform.* **14**, 193-202. (2013).
- 841 53 Pouseele, H. & Supply, P. Accurate whole-genome sequencing-based epidemiological  
842 surveillance of mycobacterium tuberculosis. *Methods in Microbiology.*  
843 doi:10.1016/bs.mim.2015.04.001 (2015).
- 844 54 Huson, D. H. & Bryant, D. Application of phylogenetic networks in evolutionary  
845 studies. *Mol Biol Evol* **23**, 254-267 (2006).
- 846 55 Brosch, R. *et al.* Comparative genomics uncovers large tandem chromosomal  
847 duplications in *Mycobacterium bovis* BCG Pasteur. *Yeast* **17**, 111-123. (2000).
- 848 56 Brosch, R. *et al.* Use of a *Mycobacterium tuberculosis* H37Rv bacterial artificial  
849 chromosome library for genome mapping, sequencing, and comparative genomics.  
850 *Infect Immun* **66**, 2221-2229 (1998).
- 851 57 Pham, T. T., Jacobs-Sera, D., Pedulla, M. L., Hendrix, R. W. & Hatfull, G. F.  
852 Comparative genomic analysis of mycobacteriophage Tweety: evolutionary insights  
853 and construction of compatible site-specific integration vectors for mycobacteria.  
854 *Microbiology.* **153**, 2711-2723 (2007).

855 58 Cascioferro, A. *et al.* Xer site-specific recombination, an efficient tool to introduce  
856 unmarked deletions into mycobacteria. *Appl Environ Microbiol* **76**, 5312-5316 (2010).  
857 59 Delogu, G. *et al.* Rv1818c-encoded PE\_PGRS protein of *Mycobacterium tuberculosis*  
858 is surface exposed and influences bacterial cell structure. *Mol Microbiol* **52**, 725-733  
859 (2004).  
860 60 Majlessi, L. *et al.* Influence of ESAT-6 Secretion System 1 (RD1) of *Mycobacterium*  
861 *tuberculosis* on the Interaction between Mycobacteria and the Host Immune System. *J*  
862 *Immunol* **174**, 3570-3579 (2005).  
863


**A**




**B**










**C**









**D**



**A***M. canettii***B****C**




**A****B****C****D**





# Mycobacterium tuberculosis complex

# Mycobacterium canettii strain pool



0.01